Adherence to alendronate in male veterans

Osteoporosis International

Volumn 19, Issue 3, 2008, Pages 349-356

  Hansen, K E ^a,b   Swenson, E D ^a   Baltz, B ^b   Schuna, A A ^c   Jones, A N ^a,b   Elliott, M E ^b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

Adherence; Alendronate; Medication possession ratio; Men; Osteoporosis; Treatment

Indexed keywords

ALENDRONIC ACID; CALCIUM; MULTIVITAMIN; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITOMETRY; BONE DISEASE; BONE MASS; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING HABIT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VETERAN;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; VETERANS;

EID: 38849117800     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0471-4     Document Type: Article

References (45)

1. Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81:646-656
2. (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
3. (2003) Physician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation: Washington, DC
4. Binkley N, Krueger D (2002) Osteoporosis in men. WMJ 101:28-32
5. Compston J (2001) Secondary causes of osteoporosis in men. Calcif Tissue Int 69:193-195
6. Kelepouris N, Harper KD, Gannon F et al (1995) Severe osteoporosis in men. Ann Intern Med 123:452-460
7. Riggs BL, Khosla S, Melton LJ 3rd (1998) A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763-773
8. Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604-610
9. Adachi JD, Saag KG, Delmas PD et al (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202-211
10. Wallach S, Cohen S, Reid DM et al (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277-285
11. Finkelstein JS, Hayes A, Hunzelman JL et al (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226
12. Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17
13. Badamgarav E, Fitzpatrick LA (2006) A new look at osteoporosis outcomes: the influence of treatment, compliance, persistence, and adherence. Mayo Clin Proc 81:1009-1012
14. Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008
15. McCombs JS, Thiebaud P, McLaughlin-Miley C et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271-287
16. Siris ES, Harris ST, Rosen CJ et al (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022
17. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928
18. Weycker D, Macarios D, Edelsberg J et al (2006) Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 17:1645-1652
19. Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856-861
20. Solomon DH, Avorn J, Katz JN et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414-2419
21. Yood RA, Emani S, Reed JI et al (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965-968
22. Papaioannou A, Ioannidis G, Adachi JD et al (2003) Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808-813
23. Curtis, JR, Westfall AO, Allison JJ et al (2006) Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int 17:1268-1274
24. Cooper A, Drake J, Brankin E (2006) Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 60:896-905
25. Rossini M, Bianchi G, Di Munno O et al (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914-921
26. Gold DT, Alexander IM, Ettinger MP (2006) How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother 40:1143-1150
27. Lo JC, Pressman AR, Omar MA et al (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922-928
28. Downey TW, Foltz SH, Boccuzzi SJ et al (2006) Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 99:570-575
29. Ensrud KE, Barrett-Connor EL, Schwartz A et al (2004) Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 19:1259-1269
30. Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
31. Fisher L, Belle GV (1993) Biostatistics: a methodology for the health sciences. Wiley, New York
32. Vik SA, Hogan DB, Patten SB et al (2006) Medication nonadherence and subsequent risk of hospitalisation and mortality among older adults. Drugs Aging 23:345-356
33. Barr RG, Somers SC, Speizer FE et al (2002) Patient factors and medication guideline adherence among older women with asthma. Arch Intern Med 162:1761-1768
34. Lavigne M, Rocher I, Steensma C et al (2006) The impact of smoking on adherence to treatment for latent tuberculosis infection. BMC Public Health 6:66
35. Law MR, Hackshaw AK (1997) A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 315:841-846
36. Solomon DH, Avorn J (2003) Pharmacoepidemiology and rheumatic diseases: 2001-2002. Curr Opin Rheumatol 15:122-126
37. Morris AB, Li J, Kroenke K et al (2006) Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy 26:483-492
38. Benner JS, Glynn RJ, Mogun H et al (2002) Long-term persistence in use of statin therapy in elderly patients. JAMA 288:455-461
39. Carr AJ, Thompson PW, Cooper C (2006) Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 17:1638-1644
40. Miller PD, Woodson G, Licata AA et al (2000) Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 22:1433-1442
41. Compston JE, Seeman E (2006) Compliance with osteoporosis therapy is the weakest link. Lancet 368:973-974
42. Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117-1123
43. Wu JY, Leung WY, Chang S et al (2006) Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ 333:522
44. Raynor DK, Booth TG, Blenkinsopp A (1993) Effects of computer generated reminder charts on patients' compliance with drug regimens. BMJ 306:1158-1161
45. Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487-497